NCIt definition : An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with
potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated
and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant
missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including
those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast
growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor
TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib
may result in the inhibition of cellular proliferation and angiogenesis and may induce
cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.;